Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Capricor Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $47.67 Mil. Capricor Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $32.80 Mil. Capricor Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $355.95 Mil. Therefore, Capricor Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.04.
Capricor Therapeutics Scaled Net Operating Assets Related Terms
Capricor Therapeutics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Capricor Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics Scaled Net Operating Assets Chart
CAPR vs SNDX, SLS, AGIO: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Capricor Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.04 mean?
Capricor Therapeutics (CAPR) has a Scaled Net Operating Assets of 0.04 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Scaled Net Operating Assets too high?
Capricor Therapeutics' current Scaled Net Operating Assets is 0.04. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Scaled Net Operating Assets compare to SNDX and SLS?
Capricor Therapeutics' Scaled Net Operating Assets of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Scaled Net Operating Assets is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $29.51 — trading 506% above its estimated fair value. The current Scaled Net Operating Assets is 0.04. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Scaled Net Operating Assets is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $29.51 is trading 506% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Scaled Net Operating Assets: 0.04
GF Value™: $4.87 vs. price of $29.51 (506% above fair value)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
